---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-014968"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2024-02-16T23:59:59+00:00"
generated_at: "2026-06-06T00:35:05.598919+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nektar repurchases 8.28M shares from BMS for $3M; reduces outstanding shares by 4.34%

## Summary
- Purchased 8,284,600 BMS-held restricted shares for $3,000,000 aggregate.
- Stock repurchase reduces outstanding shares by ~4.34% based on Nov 2023 10-Q count.
- 2018 Share Purchase Agreement and Investor Agreement with BMS terminated.
- Reduction reflected in weighted-average shares for quarter ending June 30, 2024.

## SEC filing metadata
- accession: 0001213900-24-014968
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2024-02-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.02, 1.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390024014968/0001213900-24-014968-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390024014968/ea190567-8k_nektarther.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-014968
- JSON: https://secwatch.observer/filing/0001213900-24-014968.json
- Plain text: https://secwatch.observer/filing/0001213900-24-014968.txt

## Key facts
- Material Agreements
  NEKTAR THERAPEUTICS terminated share purchase agreement with Bristol-Myers Squibb Company (effective 2024-02-12).
  - Action: termination
  - Agreement: equity purchase
  - Counterparty: Bristol-Myers Squibb Company
  - Effective: 2024-02-12
  source text: Nektar entered into a privately negotiated Stock Repurchase Agreement with BMS pursuant to which, among other things, Nektar purchased from BMS all of the BMS Nektar Shares (the “Stock Repurchase”) for an aggregate purchase price of $3,000,000 and all rights and obligations of the parties under the Purchase Agreement and the IA were terminated.
  evidence_url: https://www.sec.gov/Archives/edgar/data/906709/000121390024014968/0001213900-24-014968-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.